S-1: Helius Medical Technologies Files S-1 for Public Offering Amidst Nasdaq Delisting Concerns and Significant Dilution Risks

Helius Medical Technologies, a neurotechnology company, has filed an S-1 registration statement for a public offering of common stock and warrants, seeking to raise approximately $13.6 million to address immediate financial needs and Nasdaq listing compliance, while facing substantial dilution for new investors.

Summary

• Helius Medical Technologies is conducting a 'best efforts' public offering of 3,448,275 shares of Class A common stock and common warrants, with an assumed combined public offering price of $4.35 per share and accompanying common warrant, based on the May 21, 2025 Nasdaq closing price.
• The offering also includes pre-funded warrants for certain purchasers, priced at $4.349 per underlying share with a nominal exercise price of $0.001.
• The common warrants have an initial exercise price of $9.79 per share (225% of the public offering price) and expire 2.5 years after issuance.
• A 'zero cash exercise' option for common warrants allows holders to receive an aggregate number of shares equal to twice the shares issuable upon a cash exercise, without additional cash payment, during the first 90 calendar days post-issuance.
• The company anticipates receiving no additional funds from the exercise of common warrants due to the zero cash exercise option, which could result in the issuance of up to 51,724,125 shares if exercised at the floor price of $4.35.
• Common warrant exercise terms will reset on the 5th and 10th trading days after issuance, adjusting the exercise price based on VWAP and Nasdaq closing prices, subject to a floor price of 30% of the most recent Nasdaq Official Closing Price preceding the securities purchase agreement.
• Net proceeds from the offering are estimated at approximately $13.6 million, which will be used to repay $1,560,000 in outstanding unsecured 20% original issue discount promissory notes and for working capital and general corporate purposes.
• The company's product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device cleared in the U.S. for gait deficit due to mild-to-moderate multiple sclerosis symptoms (adjunct to physical therapy) and authorized in Canada for chronic balance deficit due to mild-to-moderate traumatic brain injury, gait deficit due to MS, and gait deficit due to stroke.
• Helius Medical Technologies is a 'smaller reporting company' and has elected to comply with reduced public company reporting requirements.
• As of March 31, 2025, the company's actual cash and cash equivalents were $1,109,000, with a total stockholders' equity of $1,280,000.
• Pro forma as adjusted for this offering, cash and cash equivalents are projected to be $14,305,000, and total stockholders' equity $15,156,000.
• The company's independent registered public accounting firm included an explanatory paragraph in its report for the year ended December 31, 2024, stating that recurring losses and net capital deficiency raise substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the 'going concern' warning, severe dilution from the offering, ongoing Nasdaq non-compliance issues, and the structure of the warrants which are unlikely to bring in additional cash upon exercise. While the capital raise provides short-term liquidity, the underlying financial instability and dilutive terms overshadow any positives.

Positives

• The offering is expected to raise approximately $13.6 million in net proceeds, which will be used to repay outstanding debt and provide working capital.
• The company's stockholders approved an increase in authorized common stock to 800,000,000 shares, providing flexibility for future capital raises or strategic initiatives.
• Stockholders also approved the issuance of up to 148,621,326 shares in a potential financing, indicating shareholder support for capital-raising efforts.
• The company received an extension from Nasdaq until June 30, 2025, to regain compliance with both the Minimum Bid Price Requirement and the Stockholders Equity Requirement, temporarily averting delisting.

Negatives

• The offering is highly dilutive, with new investors incurring an immediate and substantial dilution of $0.68 per share based on the assumed offering price.
• The 'zero cash exercise' option for common warrants means the company will likely not receive any additional funds upon their exercise, despite the potential for up to 51,724,125 shares to be issued.
• The company is not in compliance with Nasdaq's continued listing requirements regarding minimum bid price and stockholders' equity, facing potential delisting if compliance is not regained by June 30, 2025.
• The company's independent auditor has raised 'substantial doubt about our ability to continue as a going concern' due to recurring losses and net capital deficiency.
• There is no established trading market for the common warrants or pre-funded warrants, limiting their liquidity.
• The exercise price of certain existing warrants (2022 Warrants) may be decreased by this offering, potentially reducing future proceeds from their exercise.

Risks

• Nasdaq may delist the company's Common Stock for public interest concerns due to the highly dilutive nature of the offering, even if other compliance is met.
• The company's stock price may fall below Nasdaq's minimum bid price as a result of this offering, leading to delisting.
• The public offering price does not necessarily indicate the actual or market value of the common stock.
• The company will likely not receive any additional funds upon the exercise of the common warrants due to the zero cash exercise option, leading to severe dilution without corresponding cash inflow.
• Investors purchasing common stock in this offering will incur immediate and substantial dilution in the net tangible book value of their shares.
• Future sales or dilution of equity, including from common warrant exercises, could adversely affect the market price of the common stock.
• Management has broad discretion in the use of proceeds, and funds may not be used effectively to increase investment value.
• The market price of the company's common stock may be highly volatile.
• The company's ability to continue as a going concern is in substantial doubt, and failure to obtain sufficient funding could lead to liquidation.
• There is no public market for the common warrants or pre-funded warrants, limiting their liquidity.
• Holders of common warrants and pre-funded warrants have no rights as stockholders until exercise.

Future Outlook

The company's future outlook is heavily dependent on its ability to raise sufficient capital through this offering and maintain its Nasdaq listing. It expects expenses to increase as it continues clinical trials for PoNS Therapy and pursues further regulatory approvals, while also building commercial infrastructure. The company aims to obtain national Medicare insurance coverage and a reimbursement code for PoNS. However, the independent auditor's 'going concern' warning highlights significant uncertainty regarding the company's ability to continue operations without additional funding.

Management Comments

• "We believe it is highly unlikely that a holder of the common warrants would pay an exercise price in cash to receive one share of common stock when the holder could instead choose the zero cash exercise option and pay no cash to receive up to fifteen (15) shares of common stock if the exercise price decreases to and equals the floor price at the time of such election."
• "As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the common warrants."
• "While we believe that the Special Meeting Stockholder Approvals mitigates the public interest concerns that Nasdaq has identified, there can be no assurance that Nasdaq will agree and our common stock may be delisted from Nasdaq."
• "We intend to reinvest earnings, if any, in the development and expansion of our business."
• "We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules."

Industry Context

Helius Medical Technologies operates in the neurotechnology sector, focusing on non-implantable medical devices for neurological conditions. Its flagship product, PoNS, targets gait and balance deficits associated with conditions like multiple sclerosis, traumatic brain injury, and stroke. The market for neurological rehabilitation devices is growing, driven by an aging population and increasing prevalence of neurological disorders. However, the company faces challenges common to early-stage medical device companies, including securing adequate reimbursement coverage, building commercial infrastructure, and navigating complex regulatory pathways. The highly dilutive nature of this offering and the 'going concern' warning suggest the company is in a critical financial position, which is not uncommon for small-cap biotech/medtech firms that require significant capital for R&D and commercialization before achieving profitability.

Comparison to Industry Standards

• The company's PoNS device has received marketing clearance in the U.S. for MS-related gait deficit and authorization in Canada for MS, mmTBI, and stroke-related gait/balance deficits. This multi-indication authorization in Canada suggests broader applicability than its current U.S. clearance, which could be a positive differentiator if expanded.
• The company's financial health, as indicated by recurring losses and a net capital deficiency, is below industry standards for established, profitable medical device companies. This is typical for development-stage companies but raises significant concerns about long-term viability without substantial additional funding.
• The reliance on highly dilutive financing structures, such as warrants with zero-cash exercise options and reset features, is a red flag compared to more stable financing methods used by mature industry players. This indicates a challenging capital-raising environment for the company.
• The ongoing Nasdaq non-compliance issues (minimum bid price, stockholders' equity) are a significant deviation from the listing standards maintained by most publicly traded medical technology companies, signaling instability and potential loss of investor confidence.
• The 'going concern' opinion from the independent auditor is a critical indicator of financial distress, a situation that is not standard for healthy, publicly traded companies in the medical device industry and typically prompts heightened scrutiny from investors and regulators.

Corporate Governance

Legal Proceedings

• The company is not in compliance with Nasdaq's minimum bid price requirement and minimum stockholders' equity requirement, leading to a delisting threat and a hearing with the Nasdaq Hearings Panel on March 18, 2025. An extension was granted until June 30, 2025, to regain compliance.

Related Party Transactions

• The company engaged Roth Capital Partners, LLC as a financial advisor for the warrant inducement transactions and paid Roth $0.2 million for its services, in addition to reimbursement for certain expenses.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience significant dilution from the current offering and potential future warrant exercises. The ongoing Nasdaq compliance issues pose a risk of delisting, which could negatively impact liquidity and stock price. The 'going concern' warning indicates a risk of substantial or complete loss of investment.
• **New Investors**: New investors will face immediate and substantial dilution. The structure of the warrants, particularly the zero-cash exercise option, means the company will likely not receive additional cash from warrant exercises, further impacting the value of their investment.
• **Employees**: The company's financial instability and Nasdaq listing uncertainty could affect employee morale and retention. The amendment to the equity incentive plan aims to provide continued equity compensation, which could be a positive for retention.
• **Creditors**: The proceeds from this offering are intended to repay outstanding promissory notes, which is positive for those specific creditors. However, the 'going concern' warning indicates broader risks for other creditors if the company cannot achieve sustained profitability or secure further funding.
• **Customers/Patients**: Continued operation and development of the PoNS device are crucial for patients relying on the therapy. Financial instability could impact the company's ability to support and further develop its product.

Next Steps

• The company intends to use the net proceeds from this offering to repay outstanding promissory notes and for working capital and general corporate purposes.
• The company must regain compliance with Nasdaq's Minimum Bid Price and Stockholders Equity Requirements by June 30, 2025, to avoid delisting.
• The company has agreed to hold annual or special meetings of stockholders to obtain approval for the exercise of the Inducement Warrants, calling a meeting every 90 calendar days until approval is obtained.
• The company will continue to conduct trials of PoNS Therapy and pursue further regulatory approvals.
• The company plans to maintain, expand, and protect its intellectual property portfolio.
• The company is seeking a business partner to commercialize and distribute PoNS in Australia.

Key Dates

Recommendation

Keywords

Helius Medical Technologies, PoNS, Neurotechnology, Medical Device, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, SEC Filing, S-1, Nasdaq Listing, Delisting Risk, Dilution, Capital Raise, Going Concern, Gait Deficit, Balance Deficit, Multiple Sclerosis, Traumatic Brain Injury, Stroke